JAGX Stock Catalyst: Jaguar Health Awarded $240,000 FDA Grant for Canalevia-CA1

Jan 12, 2026 · 4:10am ET

Grant supports treatment of chemotherapy-induced diarrhea in dogs.

Max move

+31.3%

High of day $46.77

Sparker timei

4:10am ET

JAGX · Jan 12, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Jaguar Health, Inc. (XNAS: JAGX) announced it has been awarded a $240,000 grant by the U.S. Food and Drug Administration (FDA) to support the development of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

The grant amount is $240,000. Jaguar Health has a free float of 2,473,900 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time JAGX sparks.

Download Sniper App →

Catch the next JAGX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →